［1］Nash K，Hafeez A，Hou S.Hospital-acquired renal insufficiency［J］.Am J Kidney Dis，2002，39：930-936.
［2］Mehran R.Nikolsky E.Contrast-induced nephropathy：Definition，epidemiology，and patients at risk［J］.Kidney Int，2006，69：S11-15.
［3］Waikar SS，Curhan GC，Wald R，et al.Declining mortality in patients with acute renal failure，1988 to 2002［J］.J Am Soc Nephrol，2006，17：1143-1150.
［4］Michael R，Harold F.Contrast-induced nephropathy：What are the ture clinical consequences［J］?American Society of Nephrology，2008，3（1）：263-272.
［5］Daniele Bissacco.Contrast-induced nephropathy(CIN)：A rapid overview for risk assessment and prevention［J］.Euromediterranean Biomedical Journal，2017，12(26)：125-129.
［6］Cao RH，Ye P，Liu Y，et al.A report about the cusing factors in contrast nephropathy［J］.Chinese Journal of Practical Internal Medicine，2010，30(3)：258-260.［曹瑞华，叶平，刘源，等.造影剂肾病发生的临床相关因素分析［J］.中国实用内科杂志，2010，30(3)：258-260.］
［7］Zhang P，Ni ZH，Wang L，et al.Investigation of risk factors of contrast-induced nephropathy in multi-centers after coronary artery invervention［J］.Chinese Journal of Integrated Traditional and Western Nephrology，2010，11(3)：214-217.［张翩，倪兆慧，王玲，等.冠状动脉介入术患者造影剂肾病的危险因素多中心调查［J］.中国中西医结合肾病杂志，2010，11（3）：214-218.］
［8］Han YL.Contrast-induced acute kidney injury［J］.Med J Chin PLA，2014，39（4）：255-258.［韩雅玲.重视对比剂诱导的急性肾损伤［J］.解放军医学杂志，2014，39（4）：255-258.］
［9］Li X，Li DT，Zhang BR.Risk factors of contrast-induced acute kidney injury and mortality［J］.Chinese Journal of Practical Internal Medicine，2013，33（1）：42-45.［李雪，李德天，张蓓茹.造影剂引起急性肾损伤及死亡危险因素分析［J］.中国实用内科杂志，2013，33（1）：42-45.］
［10］Bao WF，Fang L，Shi YF，et al.The development of contrast-induced nephropath［J］.Chinese Journal of Integrated Traditional and Western Nephrology，2016，17(3)：277-278.［鲍文芳，方路，施映枫，等.造影剂肾病的研究进展［J］.中国中西医结合肾病杂志，2016，17（3）：277-280.］
［11］Goldenberg I，Chonchol M，Guetta V.Reversible acute kidney injury following contrast exposure and the risk of long-term mortality［J］.Am J Neprhol，2009，29：136-144.
［12］Sigterman TA，Krasznai AG，Snoeijs MG,et al.Contrast induced nephropathy and long-term renal decline after percutaneous transluminal angioplasty for symptomatic peripheral arterial disease［J］.Eur J Vasc Endovasc Surg，2016，51：386-393.
［13］Goldfarb S，McCullough PA，McDermott J，et al.Contrast-induced acute kidney injury：Specialty-specific protocols for interventional radiology，diagnostic computed tomography radiology，and interventional cardiology［J］.Mayo Clin Proc，2009，84：170-179.
［14］Cruz DN，Perazella MA，Bellomo R，et al.Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy：A systematic review［J］.Am J Kidney Dis，2006，48：361-371.
［15］Wang N，Qian P，Kumar S，et al.The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury：A systematic review and trial sequential analysis［J］.Int J Cardiol，2016，209：319-327.
［16］Weisbord SD，Gallagher M，Kaufman J，et al.Prevention of contrastinduced AKI：A review of published trials and the design of the prevention of serious adverse events following angiography(PRESERVE) trial［J］.Clin J Am Soc Nephrol，2013，8：1618-1631.
［17］Layton JB，Kshirasagar AV，Simpson RJ，et al.Effect of statin ues on acute kidney injury risk following coronary artery bypass grafting［J］.Am J Cardiol，2013，111（6）：823-828.
［18］Patti G，Ricottini E，Nusca A，et al.Short-term，high-dose atorvastatin pretreatment to contrast-induced nephropathy in patients with coronary ARMYDA-CIN（atorvastatin for reduction of myocardial damaga during angioplasty-induced nephropathy）trial［J］.Am J Cardiol，2011，108（1）：1-7.